Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016', provides in depth analysis on Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted pipeline therapeutics. The report provides comprehensive information on the Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - The report reviews Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics and enlists all their major and minor projects - The report assesses Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table Of Content
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) Overview 7 Therapeutics Development 8 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Products under Development by Stage of Development 8 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Products under Development by Therapy Area 9 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Products under Development by Indication 10 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Products under Development by Companies 13 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Assessment 15 Assessment by Monotherapy/Combination Products 15 Assessment by Mechanism of Action 16 Assessment by Route of Administration 17 Assessment by Molecule Type 18 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Companies Involved in Therapeutics Development 19 Albireo AB 19 CJ HealthCare Corp. 20 GlaxoSmithKline Plc 21 Shire Plc 22 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Drug Profiles 23 A-4250 - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 CJ-14199 - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 Drug to Inhibit IBAT for Liver and Metabolic Diseases - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 elobixibat - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 GSK-2330672 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 maralixibat chloride - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 SC-435 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 volixibat potassium - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Dormant Projects 36 Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Featured News & Press Releases 37 Jul 29, 2016: Shire SHP626 (Volixibat) Receives FDA Fast Track Designation for an Investigational Treatment for Adults Who Have Nonalcoholic Steatohepatitis (NASH) With Liver Fibrosis 37 Jun 13, 2016: Shire Receives FDA Breakthrough Therapy Designation for Investigational Product SHP625 for Rare Gastrointestinal Condition 37 Nov 12, 2015: Albireo to Present A4250 Clinical Data at the 2015 AASLD Annual Meeting 38 Nov 10, 2015: Albireo Announces the Initiation in Japan of a Phase 3 Clinical Trial of Elobixibat in Chronic Constipation by Ajinomoto Pharmaceuticals 38 Apr 09, 2015: Shire Reports Topline Results from First of Three Placebo-Controlled Phase 2 Studies of SHP625 (LUM001) in Children with Alagille Syndrome 39 Feb 05, 2015: Initiation of a Phase II Trial for A4250, the Company's Lead Compound for Cholestatic Liver Diseases and NASH 40 May 09, 2014: Lumena Pharmaceuticals Now Dosing Patients in the INDIGO Phase 2 Clinical Trial of LUM001 in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis 40 Apr 11, 2014: Albireo's Lead Compound in Cholestatic Liver Diseases, A4250, Protects Against Bile Acid-Mediated Cholestatic Liver Injury in Mice 41 Nov 05, 2013: Inhibition of ASBT Improves Liver Function in an Animal Model of Cholestatic Liver Disease 43 Oct 29, 2013: Lumena Pharmaceuticals Initiates the CLARITY Phase II Study of LUM001 in Patients with Primary Biliary Cirrhosis 44 Sep 26, 2013: Lumena Pharmaceuticals Launches Global Clinical Program to Evaluate Safety and Efficacy of LUM001 in Children with Alagille Syndrome 45 Sep 26, 2013: Lumena Pharmaceuticals Receives Orphan Drug Designation from US Food & Drug Administration for LUM001 in Four Rare Liver Diseases 46 May 02, 2013: Ferring Pharma Begins Phase III Trials Of Elobixibat For Chronic Idiopathic Constipation 47 Nov 08, 2012: Albireo Receives Orphan Drug Designation For A4250 From FDA For Treatment Of Progressive Familial Intrahepatic Cholestasis And For Primary Biliary Cirrhosis 47 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List Of Tables
Number of Products under Development for, H2 2016 8 Number of Products under Development by Therapy Area, H2 2016 9 Number of Products under Development by Indication, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Number of Products under Development by Companies, H2 2016 13 Products under Development by Companies, H2 2016 14 Assessment by Monotherapy/Combination Products, H2 2016 15 Number of Products by Stage and Mechanism of Action, H2 2016 16 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Albireo AB, H2 2016 19 Pipeline by CJ HealthCare Corp., H2 2016 20 Pipeline by GlaxoSmithKline Plc, H2 2016 21 Pipeline by Shire Plc, H2 2016 22 Dormant Projects, H2 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
